The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2025 | Exarafenib shows promise in treating BRAF-mutant NSCLC
Tadashi Manabe, MD, PhD, University of California, San Francisco, CA, discusses the mechanism and preclinical efficacy of exarafenib, a novel pan-RAF inhibitor targeting both monomeric and dimeric RAF forms in BRAF-mutated non-small cell lung cancer (NSCLC). This includes Class II and III mutations, which currently lack approved targeted therapies and are linked to poorer outcomes. Exarafenib demonstrated potent MAPK pathway inhibition, strong anti-tumor activity, and favorable pharmacologic properties. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
